The Organ Protection of Astragalus in Subjects With Metabolic Syndrome
NCT ID: NCT01847807
Last Updated: 2015-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
210 participants
INTERVENTIONAL
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
NCT07034807
Effects of Graptopetalum Paraguayense E. Walther on the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome
NCT01463748
Improvement of Insulin Resistance With Traditional Chinese Treatment in Patients With Type 2 Diabetes
NCT00704236
To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome
NCT06515652
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
NCT02231125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-dose Astragalus group
treatment with 10 gram astragalus
high dose astagalus
Low-dose Astragalus group
treatment with 5 gram astragalus
low dose Astragalus
MS control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low dose Astragalus
high dose astagalus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. non-allergic with the astragalus
3. agree to conduct clinical trials and those who signed the informed consent
Exclusion Criteria
2. renal disease requiring dialysis
3. heart failure NYHA ⅢorⅣ;
4. complications of diabetes
5. arteritis
6. cancer
7. thyroid disease
8. unstable coronary heart disease
9. peripheral vascular disease
10. acute cerebral vascular disease11.pregnancy、 planned pregnancy
11. patients with anti-oxidants
12. acute infection
13. other organic dysfunction, such as the liver, respiratory system, blood system, and other rheumatic diseases.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LanZhou University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jing Yu
cheif of cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS2304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.